TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022

Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.

Benoit You et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.